CompletedNot Applicable

Nerve Growth Factor for the Treatment of Cornea Disease

United States5 participantsStarted 2020-10-14

Plain-language summary

To determine the efficacy and safety of nerve growth factor in the treatment of limbal stem cell deficiency (LSCD) associated with neurotrophic cornea.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Active ocular infection
✕. Anticipated need for bandage contact lens, amniotic membrane graft, or tarsorrhaphy during the study period
✕. Unable to discontinue the use of contact lens
✕. Visual acuity worse than 20/200 in the better eye

What they're measuring

Size of abnormal epithelium

Timeframe: Baseline, week 8

Trial details

NCT IDNCT04552730

SponsorStanford University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-05-04

View on ClinicalTrials.gov More Neurotrophic Keratitis trials